Successful collection of peripheral blood stem cells upon <scp>VIDE</scp> chemomobilization in sarcoma patients

Kriegsmann, Katharina; Heilig, Christoph E.; Cremer, Martin; Novotný, Jan Philipp; Kriegsmann, Mark; Brückner, Thomas; Müller‐Tidow, Carsten; Egerer, Gerlinde; Wuchter, Patrick

doi:10.1111/ejh.12960

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in this reported cohort of 42 patients, two patients with insufficient mobilization received additional treatment with plerixafor. 5 The mobilization of the study's patients was performed with G-CSF alone, without addition of other mobilization factors.…”

Section: Discussionmentioning

confidence: 99%

“…Our data are in line with Kriegsmann et al, who reported about the mobilization data after first‐line treatment with VIDE in patients with soft tissue sarcoma in both pediatric and adult population (median age 28), showing the collections to be feasible even after the third course VIDE, but indicating the need for multiple leukapheresis sessions in later courses. Furthermore, in this reported cohort of 42 patients, two patients with insufficient mobilization received additional treatment with plerixafor 5 . The mobilization of the study's patients was performed with G‐CSF alone, without addition of other mobilization factors.…”

Section: Discussionmentioning

confidence: 99%

“…3 Previous analyses indicated the feasibility of stem cell collection in patients with Ewing sarcoma, but also included pediatric patients as well as a variety of other sarcoma entities, leaving some uncertainty in the specific case adult patients with Ewing sarcoma. 5,6 The aim of this retrospective study was to evaluate the feasibility of stem cell collections in adult patients with Ewing sarcoma and to give insights in the graft composition.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of stem cell collections in adult patients with Ewing sarcoma

et al. 2022

View full text Add to dashboard Cite

Background: Ewing sarcoma is one of the most frequent soft-tissue tumors in pediatric patients. The current treatment protocols recommend stem cell apheresis (SCA) after completion of the second course of induction therapy with vincristine, ifosfamide, doxorubicine, and etoposide (VIDE). The feasibility of SCA and graft compositions in adult patients with Ewing sarcoma have not been previously analyzed. Methods and Materials:The authors analyzed 29 stem cell collections of 19 adult patients (9 male, 10 female) at a median age of 27 (range 19-53) years mobilized after VIDE (n = 17), cyclophosphamide/topotecan (n = 1) or vincristine, dactinomycin and ifosfamide (n = 1) chemotherapy. All patients were mobilized with filgrastim 5 μg/kg twice daily from day +7 of chemotherapy. The collections were performed if CD34+ cell count in peripheral blood was >10/μL. The target yields were ≥4Â10 6 CD34+ cells/kg body weight.Results: Median CD34+ cells/μL in peripheral blood before SCA were 45.8 (range 6.7-614.4)/μL. The median cumulative yields were 10.6 (range 1.5-38.8) CD34+ cells/kg body weight and ≥2Â10 6 in all but two patients (89%). CD34, CD3, and CD56 yields in collections after the third VIDE and after later courses did not differ. Four patients underwent high-dose therapy with autologous transplantation, and all were engrafted. Discussion: Stem cell mobilization is feasible in most Ewing sarcoma patients.Additionally, the present study's data suggest that it is safe to postpone stem cell collection to a later VIDE chemotherapy cycle if medically indicated. K E Y W O R D S apheresis, autologous stem cell transplantation, Ewing sarcoma, stem cell mobilization Georg-Nikolaus Franke and Roald Pfannes contributed equally and share first authorship.Madlen Jentzsch and Vladan Vucinic contributed equally and share senior authorship.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of stem cell collections in adult patients with Ewing sarcoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…On one hand, all treatment options should be kept open for the individual patient, including HD-CHT and ABSCT in the case of relapse. To this end, PBSC collection should occur not too late in the treatment plan [30]. On the other hand, the cost for unused PBSC harvests over the years can easily add up to several million Euros in a large transplant center.…”

Section: Discussionmentioning

confidence: 99%

Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products

Kriegsmann

Wack

Pavel³

et al. 2019

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Many transplantation centers routinely collect 1 or more autologous peripheral blood stem cell (PBSC) grafts in patients with hemato-oncologic and autoimmune disorders. However, subsequent high-dose chemotherapy and autologous blood stem cell transplantation (ABSCT) are often not performed, for various reasons. Currently, little is known about the actual utilization rate of stored PBSCs. We retrospectively analyzed the collection, storage, and disposal practices of PBSC products from a large cohort of patients (n = 1020) with hematologic, oncologic, and autoimmune disorders at our institution over a 12-year period. Patients with multiple myeloma were excluded. Based on our institution-specific charges, we estimated the costs for PBSC collection/processing and storage. The median number of sufficient PBSC collections per patient in the whole cohort was 2 (range, 1 to 6). We could demonstrate that only 67% of all patients who had collected sufficient PBSCs for transplantation actually underwent ABSCT, and only a small minority of all patients (4%) underwent multiple ABSCTs. The actual use of the stored PBSC grafts varied among disease entities from >80% to 0%. From a retrospective standpoint, the collected and discarded (definitively not used) or stored (potentially not used) cryostored PBSCs were associated with considerable costs of collection, cryopreservation, and long-term cryostorage. Although keeping open the therapeutic option for future transplantations may be important, there is currently a huge discrepancy between collection/storage practices and actual utilization of the cryopreserved PBSCs, at a considerable cost and strain on patients. Our study provides a rationale for reevaluating the present standards.

show abstract

Mobilization and Collection of Peripheral Blood Stem Cells in Adults: Focus on Timing and Benchmarking

Kriegsmann

Wuchter

2019

Methods in Molecular Biology

View full text Add to dashboard Cite

Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients

Abstract: Our data demonstrate the feasibility of successful PBSC collection upon VIDE chemomobilization even after up to five cycles of induction therapy, while at the same time the increasing risk of bone marrow exhaustion with every consecutive cycle is outlined.

Cited by 4 publications

References 22 publications

Analysis of stem cell collections in adult patients with Ewing sarcoma

Analysis of stem cell collections in adult patients with Ewing sarcoma

Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products

Mobilization and Collection of Peripheral Blood Stem Cells in Adults: Focus on Timing and Benchmarking

Contact Info

Product

Resources

About